{"id":"https://openalex.org/W7224110899","doi":"https://doi.org/10.3389/fphar.2026.1999276","title":"AI-enabled drug repurposing in Alzheimer\u2019s disease: from computational nomination to pharmacological proof","display_name":"AI-enabled drug repurposing in Alzheimer\u2019s disease: from computational nomination to pharmacological proof","publication_year":2026,"publication_date":"2026-10-28","ids":{"openalex":"https://openalex.org/W7224110899","doi":"https://doi.org/10.3389/fphar.2026.1999276"},"language":"en","primary_location":{"id":"doi:10.3389/fphar.2026.1999276","doi":"https://doi.org/10.3389/fphar.2026.1999276","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2026.1999276","pdf_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1999276/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1999276/pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5151946451","display_name":"Xinzhong Li","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I874055015","display_name":"Teesside University","ror":"https://ror.org/03z28gk75","country_code":"GB","type":"education","lineage":["https://openalex.org/I874055015"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"Xinzhong Li","raw_affiliation_strings":["School of Health and Life Sciences, Teesside University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"School of Health and Life Sciences, Teesside University","institution_ids":["https://openalex.org/I874055015"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5006745559","display_name":"Illana Gozes","orcid":"https://orcid.org/0000-0001-9796-2430","observed_orcids":["https://orcid.org/0000-0001-9796-2430"]},"institutions":[{"id":"https://openalex.org/I16391192","display_name":"Tel Aviv University","ror":"https://ror.org/04mhzgx49","country_code":"IL","type":"education","lineage":["https://openalex.org/I16391192"]}],"countries":["IL"],"is_corresponding":false,"raw_author_name":"Illana Gozes","raw_affiliation_strings":["The Elton Laboratory for Molecular Neuroendocrinology, Department of Human Genetics and Computational Medicine, Gray Faculty of Medical and Health Sciences, Sagol School of Neuroscience and Adams Super Center for Brain Studies, Tel Aviv University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Elton Laboratory for Molecular Neuroendocrinology, Department of Human Genetics and Computational Medicine, Gray Faculty of Medical and Health Sciences, Sagol School of Neuroscience and Adams Super Center for Brain Studies, Tel Aviv University","institution_ids":["https://openalex.org/I16391192"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5151946451"],"corresponding_institution_ids":["https://openalex.org/I874055015"],"apc_list":{"value":3150,"currency":"CHF","value_usd":3801},"apc_paid":{"value":3150,"currency":"CHF","value_usd":3801},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.86484835,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"17","issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":0.9345999956130981,"subfield":{"id":"https://openalex.org/subfields/2737","display_name":"Physiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":0.9345999956130981,"subfield":{"id":"https://openalex.org/subfields/2737","display_name":"Physiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10211","display_name":"Computational Drug Discovery Methods","score":0.04520000144839287,"subfield":{"id":"https://openalex.org/subfields/1703","display_name":"Computational Theory and Mathematics"},"field":{"id":"https://openalex.org/fields/17","display_name":"Computer Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10009","display_name":"Dementia and Cognitive Impairment Research","score":0.014000000432133675,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/alzheimer-s-disease","display_name":"Alzheimer's disease","score":0.8640000224113464},{"id":"https://openalex.org/keywords/drug-repurposing","display_name":"drug repurposing","score":1.0},{"id":"https://openalex.org/keywords/artificial-intelligence","display_name":"artificial intelligence","score":0.6859999895095825},{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.875},{"id":"https://openalex.org/keywords/semaglutide","display_name":"semaglutide","score":0.9380000233650208},{"id":"https://openalex.org/keywords/liraglutide","display_name":"liraglutide","score":0.9980000257492065},{"id":"https://openalex.org/keywords/clinical-trial-design","display_name":"clinical trial design","score":0.4779999852180481},{"id":"https://openalex.org/keywords/evidence-synthesis","display_name":"evidence synthesis","score":0.6290000081062317},{"id":"https://openalex.org/keywords/large-language-models","display_name":"large language models","score":0.9710000157356262},{"id":"https://openalex.org/keywords/knowledge-graphs","display_name":"knowledge graphs","score":0.7549999952316284},{"id":"https://openalex.org/keywords/biomarker-stratified-trial","display_name":"biomarker-stratified trial","score":0.7889999747276306},{"id":"https://openalex.org/keywords/causal-inference","display_name":"causal inference","score":0.6629999876022339}],"concepts":[{"id":"https://openalex.org/C103637391","wikidata":"https://www.wikidata.org/wiki/Q5308921","display_name":"Drug repositioning","level":3,"score":0.6474000215530396},{"id":"https://openalex.org/C519536355","wikidata":"https://www.wikidata.org/wiki/Q21021151","display_name":"Repurposing","level":2,"score":0.5673999786376953},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.5519999861717224},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.5281000137329102},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4787999987602234},{"id":"https://openalex.org/C2776214188","wikidata":"https://www.wikidata.org/wiki/Q408386","display_name":"Inference","level":2,"score":0.46869999170303345},{"id":"https://openalex.org/C154945302","wikidata":"https://www.wikidata.org/wiki/Q11660","display_name":"Artificial intelligence","level":1,"score":0.41179999709129333},{"id":"https://openalex.org/C119857082","wikidata":"https://www.wikidata.org/wiki/Q2539","display_name":"Machine learning","level":1,"score":0.3937999904155731},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.3695000112056732},{"id":"https://openalex.org/C2909862629","wikidata":"https://www.wikidata.org/wiki/Q27261089","display_name":"Semaglutide","level":5,"score":0.3481999933719635},{"id":"https://openalex.org/C64903051","wikidata":"https://www.wikidata.org/wiki/Q2198549","display_name":"Drug development","level":3,"score":0.3418999910354614},{"id":"https://openalex.org/C174348530","wikidata":"https://www.wikidata.org/wiki/Q188635","display_name":"Bridging (networking)","level":2,"score":0.3407999873161316},{"id":"https://openalex.org/C2781308992","wikidata":"https://www.wikidata.org/wiki/Q2526479","display_name":"Liraglutide","level":4,"score":0.29249998927116394},{"id":"https://openalex.org/C60644358","wikidata":"https://www.wikidata.org/wiki/Q128570","display_name":"Bioinformatics","level":1,"score":0.29089999198913574},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.2815999984741211},{"id":"https://openalex.org/C158600405","wikidata":"https://www.wikidata.org/wiki/Q5054566","display_name":"Causal inference","level":2,"score":0.2711000144481659},{"id":"https://openalex.org/C207609745","wikidata":"https://www.wikidata.org/wiki/Q4944086","display_name":"Bootstrapping (finance)","level":2,"score":0.265500009059906},{"id":"https://openalex.org/C2775925287","wikidata":"https://www.wikidata.org/wiki/Q1156895","display_name":"Nomination","level":2,"score":0.26499998569488525},{"id":"https://openalex.org/C78780964","wikidata":"https://www.wikidata.org/wiki/Q7233193","display_name":"Position paper","level":2,"score":0.25999999046325684},{"id":"https://openalex.org/C774472","wikidata":"https://www.wikidata.org/wiki/Q6760393","display_name":"Margin (machine learning)","level":2,"score":0.25949999690055847},{"id":"https://openalex.org/C124978682","wikidata":"https://www.wikidata.org/wiki/Q1201019","display_name":"Proof of concept","level":2,"score":0.25949999690055847},{"id":"https://openalex.org/C2776442814","wikidata":"https://www.wikidata.org/wiki/Q6659956","display_name":"Lixisenatide","level":5,"score":0.2574999928474426}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.3389/fphar.2026.1999276","doi":"https://doi.org/10.3389/fphar.2026.1999276","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2026.1999276","pdf_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1999276/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},{"id":"pmh:oai:doaj.org/article:d0b5e89d2ff14e3eab652b51cd079957","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/d0b5e89d2ff14e3eab652b51cd079957","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Frontiers in Pharmacology, Vol 17 (2026)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.3389/fphar.2026.1999276","doi":"https://doi.org/10.3389/fphar.2026.1999276","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2026.1999276","pdf_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1999276/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9922999739646912}],"study_designs":[],"awards":[{"id":"https://openalex.org/G5399245372","display_name":"Targeting Circadian Clock Dysfunction in Alzheimer's Disease (TClock4AD)","funder_award_id":"EP/X030091/1","funder_id":"https://openalex.org/F4320334627","funder_display_name":"Engineering and Physical Sciences Research Council"}],"funders":[{"id":"https://openalex.org/F4320311721","display_name":"Teesside University","ror":"https://ror.org/03z28gk75"},{"id":"https://openalex.org/F4320322596","display_name":"Tel Aviv University","ror":"https://ror.org/04mhzgx49"},{"id":"https://openalex.org/F4320334627","display_name":"Engineering and Physical Sciences Research Council","ror":"https://ror.org/0439y7842"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7224110899.pdf","grobid_xml":"https://content.openalex.org/works/W7224110899.grobid-xml"},"referenced_works_count":54,"referenced_works":["https://openalex.org/W2121604817","https://openalex.org/W2263739890","https://openalex.org/W2422981416","https://openalex.org/W2489003193","https://openalex.org/W2617072792","https://openalex.org/W2826750344","https://openalex.org/W2896002881","https://openalex.org/W2916749909","https://openalex.org/W2922229918","https://openalex.org/W2976163884","https://openalex.org/W2982336643","https://openalex.org/W3041781301","https://openalex.org/W3119455494","https://openalex.org/W3130727496","https://openalex.org/W3132133099","https://openalex.org/W3205064505","https://openalex.org/W4200080541","https://openalex.org/W4206055706","https://openalex.org/W4206508717","https://openalex.org/W4214676574","https://openalex.org/W4220705385","https://openalex.org/W4223591189","https://openalex.org/W4300716359","https://openalex.org/W4310461604","https://openalex.org/W4384522480","https://openalex.org/W4386502171","https://openalex.org/W4387065040","https://openalex.org/W4391280584","https://openalex.org/W4391985998","https://openalex.org/W4392162026","https://openalex.org/W4396721167","https://openalex.org/W4399388096","https://openalex.org/W4401451182","https://openalex.org/W4403053126","https://openalex.org/W4403703331","https://openalex.org/W4405481134","https://openalex.org/W4406200740","https://openalex.org/W4406424498","https://openalex.org/W4407002276","https://openalex.org/W4407752410","https://openalex.org/W4409217570","https://openalex.org/W4411873753","https://openalex.org/W4412992742","https://openalex.org/W4413962436","https://openalex.org/W4414013411","https://openalex.org/W4415240055","https://openalex.org/W4415532073","https://openalex.org/W4416850431","https://openalex.org/W4417517383","https://openalex.org/W7117533741","https://openalex.org/W7120215812","https://openalex.org/W7139011201","https://openalex.org/W7155487736","https://openalex.org/W7162455033"],"related_works":["https://openalex.org/W7131626919","https://openalex.org/W4383618467","https://openalex.org/W4392162026","https://openalex.org/W7161240193","https://openalex.org/W7162455033","https://openalex.org/W6906573183","https://openalex.org/W4407752410","https://openalex.org/W7215866672","https://openalex.org/W4403538205","https://openalex.org/W7117327622"],"abstract_inverted_index":{"Artificial":[0],"intelligence":[1],"(AI)":[2],"has":[3,208],"expanded":[4],"the":[5,56,72,94,147],"scale":[6],"and":[7,25,46,76,87,110,113,125,140,150,200,226],"speed":[8],"of":[9,32,42,44,49,51,67,133],"drug":[10],"repurposing":[11],"in":[12,55,85,98,183,212],"Alzheimer\u2019s":[13],"disease":[14],"(AD).":[15],"Transcriptomic":[16],"signature":[17],"matching,":[18,171],"network-based":[19],"systems":[20],"pharmacology,":[21],"real-world":[22],"data":[23],"pharmacoepidemiology":[24],"multi-omics":[26],"machine":[27],"learning":[28],"have":[29],"generated":[30],"hundreds":[31],"candidate":[33,210],"drugs,":[34],"while":[35,89],"repurposed":[36],"agents":[37,54],"account":[38],"for":[39,122,154,167,178],"35%":[40],"(56":[41],"158)":[43],"drugs":[45,145],"42%":[47],"(15":[48],"36)":[50],"Phase":[52],"3":[53],"2026":[57],"AD":[58],"pipeline.":[59],"Clinical":[60],"translation,":[61],"however,":[62],"remains":[63],"unproven.":[64],"Randomised":[65],"trials":[66],"GLP-1":[68],"receptor":[69],"agonists":[70],"illustrate":[71],"gap":[73],"between":[74],"prioritisation":[75,211],"therapeutic":[77],"proof:":[78],"semaglutide":[79],"did":[80,91],"not":[81,92],"slow":[82],"clinical":[83,160,168,215],"progression":[84,155],"evoke":[86],"evoke+,":[88],"liraglutide":[90],"improve":[93],"primary":[95],"FDG-PET":[96],"endpoint":[97],"ELAD.":[99],"We":[100],"examine":[101],"four":[102],"complementary":[103],"evidence":[104,123,192],"domains,":[105,193],"defining":[106],"what":[107],"each":[108],"can":[109],"cannot":[111],"establish,":[112],"position":[114],"large":[115],"language":[116],"models":[117],"as":[118],"a":[119],"cross-cutting":[120],"tool":[121],"synthesis":[124],"knowledge-graph":[126],"reasoning":[127],"rather":[128],"than":[129,137],"an":[130],"independent":[131,191],"source":[132],"biological":[134],"evidence.":[135],"Rather":[136],"cataloguing":[138],"methods":[139],"candidates,":[141],"we":[142],"appraise":[143],"leading":[144],"at":[146],"individual-molecule":[148],"level":[149],"propose":[151],"explicit":[152,197],"criteria":[153],"from":[156],"computational":[157],"nomination":[158],"to":[159],"testing.":[161],"The":[162],"framework":[163],"defines":[164],"seven":[165],"requirements":[166],"progression:":[169],"disease-stage":[170],"adequate":[172],"site-of-action":[173],"exposure,":[174],"including":[175],"CNS":[176],"exposure":[177],"central":[179],"mechanisms,":[180],"mechanistic":[181],"validation":[182],"human-relevant":[184],"models,":[185],"biomarker-stratified":[186],"trial":[187],"design,":[188],"convergence":[189],"across":[190],"causal":[194],"inference":[195],"with":[196,203],"boundary":[198],"conditions,":[199],"mechanism-aligned":[201],"endpoints":[202],"predefined":[204],"stopping":[205],"rules.":[206],"AI":[207],"improved":[209],"AD,":[213],"but":[214],"value":[216],"will":[217],"depend":[218],"on":[219],"converting":[220],"ranked":[221],"hypotheses":[222],"into":[223],"pharmacologically":[224],"plausible":[225],"prospectively":[227],"testable":[228],"programmes.":[229]},"counts_by_year":[],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2026-10-29T00:00:00"}